/NO For distribution to public services of the United States or for distribution in the United States/
All amounts expressed in Canadian dollars, unless otherwise indicated
Toronto and Riogro, Colombia, October 06, 2025 (Globe Newswire) -Pharmacielo Ltd. (Pharmacielo or Company) (TSXV: PCLO, OTC: PCLOF), Canadian parental growth of Colombia of the leading cultivator and manufacturer Syred Florch and drug pharmacy, pharmacy, pharmacy, pharmaceuticals, pharmoBol, pharmacy, as well as pharmacy, pharmaceuticals, pharmaceutors, pharmacies, pharmacies. He announced the closure of the sale of his real estate La Margarita in Carmen -de -Variant, Antioquy, Colombia, Flores El Capiro Sa (Flores El Capiro), as well as the filing of its fifteen months that ended on March 31, 2025, proven financial reports.
La Margarita Tranding Sale Transaction
- Transaction details: A preliminary sales agreement was signed on June 5, 2025. Pharmacielo and Flores El Capiro are parties. No search fees were paid in connection with the transaction.
- Gross sale price: COP $ 26,000,000,000 (approximately $ 8.6 million).
- Credit repayment: The income was used to fully repay the outstanding loan Banco Agrario de Colombia (“Banco Agrario Loan”), for the total amount of 6,129,1444 US dollars ($ 2.1 million), including the main amount, interest and legal expenses. It is important to note that the accrued interest in the amount of approximately 900 million dollars. The United States (approximately $ 300,000) was successfully negotiated and forgiven.
- Distribution of income: After repaying the BANCO Agrario loan and other outstanding obligations in Colombia, about 4.0 million dollars. The US income is transferred to Canada for partial payment of mature debt obligations and other obligatory corporate payments.
- Strategic justification The sale of La Margarita is consistent with the Pharmacielo strategic initiative to optimize its asset portfolio and strengthen its financial situation, which allows the company to concentrate resources on basic growth capabilities in priority markets.
Mark is funny The chairman and chief executive director of Pharmacielo, commented: “This transaction is a positive step forward for Pharmacielo. Having changed the inaccurate asset and elimination of the Banco Agrario loan, we strengthened our balance and reduced our burden burden.
Resume financial indicators – the fifth quarter and the financial year, which ended on March 31, 2025
| Three months are over | Fifteen months are over | Twelve months ended | ||||||||||
| (000 -x) | March 31, 2025 | March 31, 2024 | March 31, 2025 | December 31, 2023 | ||||||||
| Income | $ | 487 | $ | 240 | $ | 3967 | $ | 1542 | ||||
| Adjusted EBITDA* (loss) | $ | (801 | ) | $ | (1264 | ) | $ | (3543 | ) | $ | (6762 | ) |
| Pure loss | $ | (2228 | ) | $ | (2420 | ) | $ | (11 370 | ) | $ | (16 298 | ) |
| Pure | $ | (0.013 | ) | $ | (0.014 | ) | $ | (0.065 | ) | $ | (0.102 | ) |
*Adjusted EBITDA (income to interest, taxes, depreciation and depreciation). The term with adjusted EBITDA has no standardized value in IFRS. Therefore, this may not be comparable to similar indicators represented by other companies.
Business prospects
- Pharmacielo continues to improve its cost structure, eliminating insignificant expenses, the correct size of its ability to grow and surgery.
- With the growth and more diversified sales over the past fifteen months, Pharmacielo is a profitable company in 2026. Currently, the company is engaged in an emphasis on Brazil and continues to participate in additional jurisdictions, such as the South African, Australia and the European Union (EU) using CBD, Distillate and GACP.
- Pharmacielo has three main initiatives to remain flexible in the emerging and constantly changing international cannabis markets:
- Clearly focused on business capabilities in World America, Australia, South Africa and strategic European markets. The company has moved from a narrow desire for EU-GMP certification to a wider, oriented to the client of the approach to quality. Supporting compliance with the EC-GMP requirements and reinforcing a reliable quality management system to meet customer audit requirements, Pharmacielo continues to provide world-class products, simultaneously optimizing operating costs and capital investments.
- The placement of the full portfolio of CBD isolates, CBD extracts, the THC extracts and the compositions from the object corresponding to the EU-GMP, providing excellent quality at competitive prices that protect the strong profits of customers. This strategy provides differentiation in international markets, growing long -term partnerships and reinforcing the position as a trusted supplier.
- An increase in the export of our certified GACP-dried cannabis flower, positioning it as a reliable raw material that customers transform and commercialize as a GMP. Consolidating sequential supply and agreeing with partners in key markets, such as Australia, Germany, Poland and Great Britain, we provide flexibility to satisfy various regulatory and commercial requirements when creating a scalable path from GMP to GMP.
To obtain more detailed information and analysis, please see financial statements and analysis of the leadership and analysis for the period ending on March 31, 2025, as published in Sedarplus.ca And Pharmacielo.comField
About pharmacy
Pharmacielo Ltd. (TSXV: PCLO, OTC: PCLOF)-Global company with headquarters in Canada, with an emphasis on ethical and sustainable processing and supply of all natural, pharmaceutical medical products of Cannabis in large channels. The main (and fully belonging) subsidiary Pharmacielo is Pharmacielo Colombia Holdings Sas, with a headquarters in its center of cultivation and processing located in Riogro, Colombia.
About Flores El Capiro
Flores El Capiro SA is a leading Colombian Flower manufacturer and exporter with long -standing operations in Carmen de Viboral, Antioquia.
To obtain additional information
Requests of the media and investors:
[email protected]
Advanced statements
This press release contains promising statements. Advanced statements can be defined by using such words as “expectation”, “expected”, “intends”, “foresee”, “believes” or variations of such words and phrases, or claim that certain actions, events or results can “may” or “will” arise or will be completed or reached.
Advanced statements can affect well -known and unknown risks, uncertainty and other factors, including changes in Pharmacielo development plans, the inability to obtain and maintain all the necessary permits of regulatory organs associated with export of Cannabinoid products and imports to other countries, the approval of TSX Exchange, and the inability to export or distribute commercial products with the help of companies with company Commercial products with the help of waiting, with the impossibilities associated with commercial products, in the expected senses, with the impossibility associated with commercial products, in the expected senses associated with environmentally friendly products associated with environmentally friendly products. Colombia, fluctuations in the market price for company products, risks associated with global economic or geopolitical uncertainty or other events, risks associated with preserving the key personnel of the company, the risk of currency exchange, competition in the pharmacy market and other risks discussed or mentioned in the “risk factors” in “Pharmacyiel”. Available in www.Sedarplus.caThe field, respectively, readers should not be considered excessive dependence on promising statements. With the exception of cases required by law, Pharmacielo is not obliged to publicly update any forecast statements, whether as a result of new information, future events or others.
Neither the venture exchange of the TSX, nor the provider of regulation services (as this term is determined in the TSX Venture Exchange policy) is not responsible for the adequacy or accuracy of this press release.
